Kökçü 2000.

Methods	Randomised controlled trial
Participants	50 women in spontaneous menopause ≥ 1 year (mean 25 months), still sexually active with a partner with no sexual problems, did not have any gynaecological surgery and had no absolute contraindication for HRT. Mean age 52 years
Interventions	Tibolone 2.5 mg/d Conjugated oestrogens (CE) 0.625 mg/d plus medroxyprogesterone acetate (MPA) 2.5 mg/d Administered for 1 year
Outcomes	Vaginal dryness/dyspareunia, vasomotor symptoms, irregular spotting/bleeding
Notes	Timing: unclear Location: Turkey Multi‐centre: no; single site
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not specified
Allocation concealment (selection bias)	Unclear risk	Not specified
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Study authors did not specify whether study drugs were identical looking. They stated that (1) the trial was single‐blind; and (2) the women did not have any previous knowledge and did not receive any information on the possible effects on sexual function of the study drugs. It is then unclear whether they were intended as "blind" just because they were not provided any information
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not specified (and not clear whether the women were blind)
Incomplete outcome data (attrition bias) All outcomes	High risk	6/50 women were not evaluated for not attending visits
Selective reporting (reporting bias)	Unclear risk	Study protocol not available
Conflict of interest	Unclear risk	No information about funding or study authors' conflicts of interest